ClinicalTrials.Veeva

Menu
M

Mountain View Clinical Research | Denver, CO

Research site
(Unclaimed)

Site insights

Top conditions

Top treatments

ENX-102
Methylone
Tanezumab
Troriluzole
Pregabalin
CYB003
Psilocybin
Ponesimod
Fenebrutinib
Troriluzule

Curious how this site stacks up to its peers?

Data sourced from clinicaltrials.gov

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Active trials

12 of 49 total trials

"A Study of a Deuterated Psilocin Analog (CYB003) in Humans With Major Depressive Disorder" (APPROACH)

The purpose of this study is to examine the efficacy, safety, and tolerability of CYB003 compared to matching placebo as adjunctive treatment in part...

Enrolling
Major Depressive Disorder
Behavioral: Psychological Support
Drug: CYB003

A Phase 3 Double-blind, Placebo-controlled Study (Part A) with an Open-label Extension (Part B) Evaluating DT120 Compared to Placebo in Major Depress...

Enrolling
Major Depressive Disorder
Other: Placebo
Drug: DT120

A Phase 3 Double-blind, Placebo-controlled Study (Part A) with an Open-label Extension (Part B) Evaluating MM120 Compared to Placebo in Major Depress...

Active, not recruiting
Major Depressive Disorder
Other: Placebo
Drug: MM120 (LSD D-Tartrate)

This Phase 2 study (protocol number VLS-01-203) will determine the efficacy, safety, and tolerability of short-term treatment with a VLS-01 transmuco...

Enrolling
Treatment Resistant Depression
Drug: VLS-01-BU Placebo
Drug: VLS-01-203 BU

A study to evaluate the efficacy and safety of fenebrutinib on disability progression and relapse rate in adult participants with RMS. Eligible parti...

Active, not recruiting
Relapsing Multiple Sclerosis
Drug: Placebo
Drug: Fenebrutinib
Status recently updated

The purpose of this study is to evaluate how well JNJ-89495120 works (anti-depressant effects) and how well it is tolerated as compared to placebo on...

Enrolling
Active, not recruiting
Depressive Disorder, Major
Drug: JNJ-89495120
Drug: Placebo

The goal of this clinical trial is to learn if ACP-211 can help treat adults with major depressive disorder (MDD) who have not improved with antidepr...

Enrolling
Depressive Disorder, Treatment-Resistant
Major Depressive Disorder (MDD)
Drug: ACP-211
Drug: Placebo

The combination drug composed of aroxybutynin and atomoxetine, designated AD109, is being developed by Apnimed for the treatment of obstructive sleep...

Invitation-only
OSA
Drug: Aroxybutynin and Atomoxetine
Locations recently updated

The purpose of this study is to know how well seltorexant works, and also to evaluate safety and maintenance effect of seltorexant compared with plac...

Enrolling
Depressive Disorder, Major
Drug: Selective Serotonin Reuptake Inhibitor (SSRI)/Serotonin-Norepinephrine Reuptake Inhibitor (SNRI)
Drug: Placebo

This is a long- term extension of the double-blind trials APPROACH (CYB003-002) and EMBRACE (CYB003-003). Its aim is to examine the safety and long-t...

Invitation-only
Major Depressive Disorder
Drug: CYB003

The main aim is to see how DONQ52 works to improve small intestinal damage and reduce celiac-related symptoms due to gluten exposure, in participants...

Enrolling
Celiac Disease
Dietary Supplement: Simulated Inadvertent Gluten Exposure (SIGE) capsule
Drug: DONQ52

The goal of this clinical trial is to learn if zelquistinel works to treat depression in adults. It will also learn about the safety of zelquistinel....

Enrolling
Major Depressive Disorder
Drug: Zelquistinel

Trial sponsors

Pfizer logo
Biohaven logo
Viatris logo
D
Acadia Pharmaceuticals logo
Actelion Pharmaceuticals logo
Apnimed logo
Chugai Pharmaceutical logo
C
E

Clinical trials

Find clinical trialsTrials by location
© Copyright 2026 Veeva Systems